Prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018–2022

Bibliographische Detailangaben
Hauptverfasser:	Rachael K. Ross, Kara E. Rudolph, Chelsea L. Shover
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Addiction
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beyond treatment response: Injection‐site reactions as part of the extended‐release buprenorphine experience
von: Julien Cabé, et al.
Veröffentlicht: (2026)

Variations in US county‐level trends in buprenorphine use, 2018–2022
von: Taylor W. Lefler, et al.
Veröffentlicht: (2025)

Extended‐release buprenorphine in pregnancy
von: Alexander Hubbell, et al.
Veröffentlicht: (2024)

A comparative study of treatment retention in opioid use disorder: Subcutaneous injectable versus sublingual buprenorphine
von: Charles Deng, et al.
Veröffentlicht: (2025)

Comparative effectiveness of extended‐release naltrexone versus buprenorphine‐naloxone on treatment interruption: Comparing findings from a reanalysis of the X:BOT RCT and harmonized target trial emulation using population‐based observational data
von: Sara Lodi, et al.
Veröffentlicht: (2025)

Commentary on Gregory et al .: Fear of precipitated opioid withdrawal should not prevent buprenorphine initiation
von: Sandra A. Springer
Veröffentlicht: (2024)

Telemedicine‐assisted buprenorphine induction versus standard of care: A randomized controlled non‐inferiority trial
von: Harpreet S. Dhillon, et al.
Veröffentlicht: (2025)

Dose‐specific clinical outcomes in patients with opioid use disorder treated with 24–32 mg/day of buprenorphine
von: Julia D’Agata Mount, et al.
Veröffentlicht: (2024)

Patient outcomes following buprenorphine treatment for opioid use disorder: A retrospective analysis of the influence of patient‐ and prescriber‐level characteristics in Massachusetts, USA
von: Gary J. Young, et al.
Veröffentlicht: (2024)

Pharmacological treatment strategies to manage precipitated withdrawal following the administration of buprenorphine in opioid use disorder: A systematic review
von: Emmert Roberts, et al.
Veröffentlicht: (2026)

The association of methadone use with physical function and frailty among persons who inject drugs
von: Grace L. Kulik, et al.
Veröffentlicht: (2025)

Secondary analysis of a combined harm‐reduction treatment and extended‐release naltrexone randomized clinical trial for alcohol use disorder: Differences across race, ethnicity and sex assigned at birth
von: Silvi C. Goldstein, et al.
Veröffentlicht: (2025)

State‐level racial and ethnic disparities in buprenorphine treatment duration in the United States
von: Huiru Dong, et al.
Veröffentlicht: (2024)

Commentary on D'Agata Mount et al.: Higher dose buprenorphine to improve retention in opioid use disorder treatment, prevent relapse, and optimize integrated care interventions
von: Paolo Mannelli
Veröffentlicht: (2024)

Low and no alcohol availability and sales in small retailers in Great Britain: A geographic longitudinal analysis from 2018 to 2022
von: Roberto Valiente, et al.
Veröffentlicht: (2026)

Prescribing practices in opioid agonist treatment and changes in compliance to clinical dosing guidelines in British Columbia, Canada
von: Brenda Carolina Guerra‐Alejos, et al.
Veröffentlicht: (2024)

Commentary on Ezard et al.: Prescribed psychostimulant medications for methamphetamine use disorder – an urgent path forward
von: Adam Bisaga
Veröffentlicht: (2025)

Impact of study design decisions on identification of treatment initiators of medications for opioid use disorder
von: Payel J. Roy, et al.
Veröffentlicht: (2025)

Differences in heroin overdose risk associated with the unregulated drug market: Insights from a supervised injecting facility in Melbourne, Australia
von: Nathan C. Stam, et al.
Veröffentlicht: (2024)

Development and evaluation of a machine learning model to predict acute care for opioid use disorder among Medicaid enrollees engaged in a community‐based treatment program
von: Lingshu Xue, et al.
Veröffentlicht: (2025)

Trajectories of medication for opioid use disorder and their impact on HIV testing among people who inject drugs in India: A longitudinal assessment of clinic‐based data
von: Allison M. McFall, et al.
Veröffentlicht: (2024)

Qualitative analysis of barriers and facilitators to healthcare engagement for people with injecting‐related invasive infections using a social ecological framework
von: Lucy O. Attwood, et al.
Veröffentlicht: (2025)

Impact of baseline methamphetamine/amphetamine use on discontinuation of methadone and buprenorphine/naloxone among people with prescription‐type opioid use disorder in Canada
von: Jenna Langlois, et al.
Veröffentlicht: (2024)

Extended‐release pharmacotherapies for substance use disorders in incarcerated populations: A systematic review
von: Amelia Woods, et al.
Veröffentlicht: (2025)

Analysis of rapid onset heroin overdose cases from a supervised injecting facility in Melbourne, Australia
von: Nathan C. Stam, et al.
Veröffentlicht: (2025)

An exploratory analysis of 5‐alpha reductase inhibitors and risk of opioid use disorder among male Medicare beneficiaries receiving prescription opioid medications
von: Abdelrahman G. Tawfik, et al.
Veröffentlicht: (2025)

Tissue‐retained needles in people who inject drugs: A systematic review of case reports and series on clinical presentations, complications and management
von: Heidi Laukkala, et al.
Veröffentlicht: (2026)

Characteristics of deaths due to drug‐related causes among individuals recently released from prison in the United Kingdom, 1997–2025
von: Emmert Roberts, et al.
Veröffentlicht: (2026)

Mortality risk among individuals who smoke opioids compared with those who inject: A propensity score‐matched cohort analysis of United States national treatment data
von: George Karandinos, et al.
Veröffentlicht: (2025)

Changing trends in drug overdose mortality in Spain, 2001–2022
von: Florencia Giné, et al.
Veröffentlicht: (2025)

Significant changes in preference of illicit drug use in a population of Hanoi, Vietnam—A 6‐year wastewater study (2018–2023)
von: Tran Thi Thanh Hue, et al.
Veröffentlicht: (2025)

Change of substance‐related hospitalisation in adolescents after cannabis legalisation in Thailand in 2022
von: Sirada Puetpaiboon, et al.
Veröffentlicht: (2026)

Trends in hallucinogen‐associated emergency department visits and hospitalizations in California, USA, from 2016 to 2022
von: Nicolas Garel, et al.
Veröffentlicht: (2024)

Patterns, reasons and characteristics of e‐cigarette use in Australia: Findings from the 2022–2023 National Drug Strategy Household Survey
von: Carmen C. W. Lim, et al.
Veröffentlicht: (2025)

Cigarette smoking across life from 1946 to 2018: Harmonisation of four British birth cohort studies
von: Liam Wright, et al.
Veröffentlicht: (2025)

Screening for addiction in the dental office: The bottom line
von: Carrigan L. Parish, et al.
Veröffentlicht: (2026)

Associations between modes of cannabis use and cannabis use disorder: Evidence from the 2022 to 2023 United States National Survey on Drug Use and Health
von: Amrit Baral, et al.
Veröffentlicht: (2026)

RETRACTION: Proportions and Correlates of High‐Risk Cannabis Use in Australia—A Cross‐Sectional Analysis of the 2022–2023 National Drug Strategy Household Survey
Veröffentlicht: (2026)

Profiles of youth initiating use of nicotine pouches, vapes and cigarettes: National findings from the Population Assessment of Tobacco and Health (PATH) study, 2022–2023
von: Olufemi Erinoso, et al.
Veröffentlicht: (2026)

RETRACTED: Proportions and correlates of high‐risk cannabis use in Australia—A cross‐sectional analysis of the 2022–2023 National Drug Strategy Household Survey
von: Janni Leung, et al.
Veröffentlicht: (2025)

Ähnliche Einträge

Ähnliche Einträge